# Junta clínica — PT-pseudo_5dc2eb70fbd7 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_5dc2eb70fbd7",
  "pid": "PT-pseudo_5dc2eb70fbd7",
  "task": 1,
  "psa": 0.44,
  "age": 63,
  "months": 1,
  "pirads": "3",
  "psad": 0.03,
  "psav": 0.0,
  "psap": 0.4,
  "vol": 29.0,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.57961565,
  "medhx": "Hypertension, Hypercholesterolaemia, Osteoarthritis",
  "meds": "amlodipine, lisinopril, metoprolol, atorvastatin, paracetamol PRN",
  "notes": "PSA 0.44 ng/mL. PI-RADS 3. PSAD 0.03. Prostate volume 29 mL. csPCa 0.58.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "84 kg",
    "height": "179 cm",
    "bmi": "26.2",
    "bp": "142/80 mmHg",
    "hr": "67 bpm",
    "smoking": "Current smoker (36 pack-yr)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "09 Feb 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent uncertainty regarding prostate cancer screening warrants re-evaluation after an earlier negative biopsy and a steady PSA course."
    },
    {
      "s": "History",
      "t": "A 63-year-old civil engineer initially entered evaluation years ago after a mildly elevated PSA triggered a systematic biopsy that returned entirely benign. He currently experiences moderate lower urinary tract symptoms, notably nocturia twice nightly and a slightly weak stream, yielding an IPSS score of 10. Medical background includes well-controlled hypertension and hypercholesterolaemia, treated with amlodipine, lisinopril, metoprolol, and atorvastatin, plus occasional paracetamol PRN for osteoarthritis. He maintains a 36 pack-year smoking history and drinks roughly 26 units of alcohol weekly. Daily fitness routines include a 20-minute walk. Beyond urological matters, he recently finished six physiotherapy sessions for mechanical lower back pain, keeps up with regular dental check-ups, and manages mild visual impairment requiring large-print materials. He lives with his wife; their adult children visit weekly, and he continues active involvement in local engineering consultancy projects."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and symmetric; consistency: normal; asymmetry/nodules: absent. Vital signs reveal a blood pressure of 142/80 mmHg and a regular heart rate of 67 beats per minute. General inspection shows no peripheral oedema, while abdominal palpation confirms the absence of suprapubic tenderness or palpable masses."
    }
  ],
  "occupation": "civil engineer",
  "marital": "Married",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions",
    "Dental — biannual check-up"
  ],
  "alcohol": "26 units / week",
  "exercise": "Walking 20 min/day",
  "ipss": "IPSS score: 10/35 (moderate LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_5dc2eb70fbd7
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 0.44 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.03 ng/mL²
  - PSA velocity: 0.0 ng/mL/yr
  - Prior PSA: 0.4 ng/mL
  - Prostate volume: 29.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.57961565 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Osteoarthritis
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Osteoarthritis
  - Current medication: amlodipine, lisinopril, metoprolol, atorvastatin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 0.44 ng/mL. PI-RADS 3. PSAD 0.03. Prostate volume 29 mL. csPCa 0.58.

Vitals: weight 84 kg, height 179 cm, BMI 26.2, BP 142/80 mmHg, HR 67 bpm. Smoking: Current smoker (36 pack-yr).

Chief complaint: Persistent uncertainty regarding prostate cancer screening warrants re-evaluation after an earlier negative biopsy and a steady PSA course.

History: A 63-year-old civil engineer initially entered evaluation years ago after a mildly elevated PSA triggered a systematic biopsy that returned entirely benign. He currently experiences moderate lower urinary tract symptoms, notably nocturia twice nightly and a slightly weak stream, yielding an IPSS score of 10. Medical background includes well-controlled hypertension and hypercholesterolaemia, treated with amlodipine, lisinopril, metoprolol, and atorvastatin, plus occasional paracetamol PRN for osteoarthritis. He maintains a 36 pack-year smoking history and drinks roughly 26 units of alcohol weekly. Daily fitness routines include a 20-minute walk. Beyond urological matters, he recently finished six physiotherapy sessions for mechanical lower back pain, keeps up with regular dental check-ups, and manages mild visual impairment requiring large-print materials. He lives with his wife; their adult children visit weekly, and he continues active involvement in local engineering consultancy projects.

Physical examination: DRE — texture: smooth and symmetric; consistency: normal; asymmetry/nodules: absent. Vital signs reveal a blood pressure of 142/80 mmHg and a regular heart rate of 67 beats per minute. General inspection shows no peripheral oedema, while abdominal palpation confirms the absence of suprapubic tenderness or palpable masses.

Patient info: civil engineer; Married; Lives with partner; adult children visit weekly.
Next of kin: Sibling (sister).

Lifestyle: alcohol 26 units / week; exercise Walking 20 min/day; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Dental — biannual check-up.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.43
  uncertainty  +/- 0.13 epistemic (95% band 0.18-0.68); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers DEFER.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 18 labelled men in this same situation (Negative prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 2.07: PI-RADS 4, PSA 0.76, PSAD 0.02, age 60, DRE Normal -> DEFER (clear). He wrote: "Low PSA with earlier negative biopsy. A change in P4 lesion size might trigger a biopsy."
  2. distance 2.55: PI-RADS 3, PSA 3.4, PSAD 0.05, age 63, DRE Normal -> DEFER (clear). He wrote: "Prev benign biopsy + PIRADS 3 (=no significant lesion) + low PSA-density -> Low longterm risk of lethal prostate cancer. 2yr too short interval for next assessment. sugg…"
  3. distance 3.31: PI-RADS 4, PSA 3.0, PSAD 0.12, age 68, DRE Normal -> BIOPSY (borderline). He wrote: "PIRADS 4 lesion in 68 year old man with heavy comorbidity. Earlier negative biopsy."

PRECEDENT: DEFER (weighted vote 0.26 for biopsy). Distance-weighted precedent is fair here (0.78 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 18 labelled traces in this situation (Negative prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines address the use of MRI and biopsy in prostate cancer diagnosis. The guideline suggests that a PI-RADS score of 3 is used to trigger a biopsy, and a PI-RADS score of 4-5 is used to trigger a biopsy. It also notes that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is contradicted by the guideline's use of PI-RADS 3 as a trigger for biopsy. Expert 4's focus on the PI-RADS score is relevant, but the guideline suggests that a stable MRI (PRECISE 1-3) does not automatically exclude a repeat biopsy.

WHAT WE STILL NEED
The guideline requires establishing the PSA density value to determine risk stratification. The panel shows the PSA density is 0.03 ng/mL², which is below the 0.15 ng/mL/cc threshold mentioned in the retrieved text. The panel also shows the prior biopsy status as Negative, which is a factor in the guideline regarding follow-up.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 3 score, combined with the low PSA density, warrants a biopsy according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the PI-RADS 3 lesion?
  psa_trend (get_psa_trend) -> What is the serial PSA trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the Gleason or ISUP grade from the prior negative biopsy?
  laboratory_results (get_lab_results) -> What are the full results for renal function and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the Gleason or ISUP grade from the prior negative biopsy notes?
  Q2. Does the PSA trend (flat/rising/falling) provide further context for the decision?
  Q3. What is the full laboratory panel, specifically regarding renal function and haemoglobin?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI Prostate
Facility: Spaarne Gasthuis, Haarlem
Date: 28 Jan 2025
PI-RADS 3 lesion in the right mid-gland peripheral zone.
COMPARISON: new

psa_trend
The serial PSA trend is flat, with values at 0.5 ng/mL on Apr 2022, 0.5 ng/mL on Apr 2023, 0.5 ng/mL on Mar 2024, and 0.5 ng/mL on Feb 2025.

previous_notes
The Gleason or ISUP grade from the prior negative biopsy was not recorded.

laboratory_results
Creatinine: 95 umol/L
Haemoglobin: 13.6 g/dL

WHAT I DID NOT OPEN
family-history of prostate cancer (anamnesis) because it was not requested by the moderator.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 3 lesion in the right mid-gland peripheral zone (radiology_report)
EAU guideline suggests biopsy for PI-RADS 3 lesions (EXPERT-EAU)

AGAINST sampling this patient now
Prior biopsy was negative (INTAKE)

WHERE THIS LEANS
The findings suggest a borderline situation where the PI-RADS 3 score aligns with the EAU guideline suggesting a biopsy trigger, despite the negative prior biopsy.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 0.50 ng/mL over 4 points spanning 34 months; velocity +0.00 ng/mL per year; no meaningful doubling time.
PROJECTION at 6 months: 0.5 ng/mL, conformal 95% band 0.1-1.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.32
  uncertainty  +/- 0.12 epistemic (95% band 0.09-0.56), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.43  ('discuss' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.32  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.26  (k=3 precedents)
  EXPERT-COHORT      DEFER  (rule pirads_le_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_le_3) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 16 of 18 labelled cases in exactly this situation (prior negative biopsy).

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—address all three moderator questions.

ALIGNMENT WITH THE PANEL
The panel protocol concluded NO BIOPSY based on the cohort criterion (PI-RADS $\le 3$), which aligns with the finding in the radiology_report showing a PI-RADS 3 lesion.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the Gleason or ISUP grade from the prior negative biopsy notes? The registrar reported that the Gleason or ISUP grade from the prior negative biopsy was not recorded.
Q2. Does the PSA trend (flat/rising/falling) provide further context for the decision? The registrar reported the serial PSA trend is flat.
Q3. What is the full laboratory panel, specifically regarding renal function and haemoglobin? The registrar reported Creatinine: 95 umol/L and Haemoglobin: 13.6 g/dL.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score (3) is highly relevant as it is the primary driver for the cohort criterion that led to the panel's decision. The PSA density (0.03 ng/mL²) is also relevant as it was noted by the EAU expert as being below the 0.15 threshold.

MY SUGGESTION TO THE CHAIR
Given that the cohort criterion fired and the retrieved data does not provide a finding that overturns the panel's decision, the current position of NO BIOPSY should be maintained.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the cohort criterion fired based on the PI-RADS 3 score, which aligns with the EAU guideline suggesting biopsy for this category, despite the prior negative biopsy. The evidence converged on deferral, as the retrieved data did not provide a specific finding to overturn the panel's conclusion. The PI-RADS 3 score was the primary driver, and the lack of a rising PSA density supported the deferral.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
